title: Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.
abstract: This study assesses the cost-effectiveness of vaccination against herpes zoster (HZ) and postherpetic neuralgia in France, using a published Markov model. The cost-effectiveness of vaccinating individuals aged from 65 years or between 70 and 79 years was evaluated over their lifetime, from a third-party payer perspective. French-specific data were combined with results from clinical studies and international quality-of-life-based (EuroQol five-dimension questionnaire) utilities from the literature. HZ vaccination was highly cost effective in both populations. Incremental cost-effective ratios were estimated between €9513 and 12,304 per quality-adjusted life year gained, corresponding to €2240-2651 per HZ case avoided and €3539-4395 per postherpetic neuralgia case avoided. In addition to epidemiological and clinical evidence, economic evidence also supports the implementation of HZ vaccination in France.
authors.affiliation: Sanofi Pasteur MSD, 8 Rue Jonas Salk, 69367 Lyon Cedex 07, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Bresse
authors.forename: Lieven
authors.initials: L
authors.lastname: Annemans
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Préaud
authors.forename: Karine
authors.initials: K
authors.lastname: Bloch
authors.forename: Gérard
authors.initials: G
authors.lastname: Duru
authors.forename: Aline
authors.initials: A
authors.lastname: Gauthier
mesh_terms: D000367:Age Factors; D000368:Aged; D003362:Cost-Benefit Analysis; D005602:France; D006562:Herpes Zoster / Q000191:economics / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D008390:Markov Chains; D051474:Neuralgia, Postherpetic / Q000191:economics / Q000517:prevention & control*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014611:Vaccination / Q000191:economics
chemical_list: D053061:Herpes Zoster Vaccine